Incidence of transfusion-induced platelet-reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies

被引:15
作者
Fontaeo-Wendel, R.
Silva, L. C. N.
Saviolo, C. B. R.
Primavera, B.
Wendel, S.
机构
[1] Hosp Sirio Libanes, Banco Sangue, BR-01308 Sao Paulo, Brazil
[2] Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, Brazil
[3] Univ Sao Paulo, Inst Coracio, Lab Imunol, Sao Paulo, Brazil
关键词
blood transfusion; HLA; HPA; platelet antibodies;
D O I
10.1111/j.1423-0410.2007.00958.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives The aim of this work was to study the incidence of transfusion-induced platelet-reactive antibodies in a selective patient population and evaluate different methodologies for platelet antibody screening (PAS). Materials and Methods The patients were retrospectively selected and divided into three separate groups: haematological malignancies (Group 1: n = 33); cardiac and orthopaedic patients (Group 2: n = 31) and a control group (Group 3: n = 23) selected with the same diagnoses of Group 2. PRE- and POST-transfusion samples were tested for PAS by the following tests: PIFT (platelet immunofluorescence test), MAIPA (monoclonal antibody immobilization of platelet antigen), Flow PRA (R) and LCT (lymphocytotoxicity test). Results There was not a 100% concordance among the methodologies used. PIFT, MAIPA and Flow PRA presented very similar results whereas that of LCT differed from the other methods. A high rate of positive results (32%) was found in the PRE samples followed by an increase of almost 50% after blood transfusion (POST samples: 42.5% of positivity), but there was a statistical difference (P < 0.05) between the PRE and POST transfusion sample only for the Flow PRA (R) technique tested on Group 2. Human leucocyte antigen (HLA) class I antibodies were present on 97.4% of POST positive samples, 5.4% presented anti-human platelet antigen (HPA)-1b antibodies and 8.1% presented a mix of panreactive antibodies against glycoprotein IIbIIIa, IaIIa and IbIX. Conclusions Blood transfusion did not increase the rate of alloimmunization in our haematological patients (Group 1); however, the patients were already admitted with a high rate of alloimmunization (12%). Group 2 patients are being immunized and the impact of this procedure remains to be studied as these patients may eventually undergo further hospitalization and receive more blood transfusion.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 30 条
[1]  
ALTMAN DG, 1991, LPRACTICAL STAT MED
[2]   Acute and delayed hemolytic transfusion reactions secondary to HLA alloimmunization [J].
Benson, K ;
Agosti, SJ ;
Latoni-Benedetti, GE ;
Leparc, GF .
TRANSFUSION, 2003, 43 (06) :753-757
[3]  
BENSON K, 1999, CURRENT ISSUES PLATE
[4]   Report on the 12th International Society of Blood Transfusion Platelet Immunology Workshop [J].
Bessos, H ;
Wilson, DWL ;
Metcalfe, P ;
Allen, D ;
Urbaniak, SJ .
VOX SANGUINIS, 2005, 89 (02) :105-113
[5]   Flow cytometry in human leukocyte antigen testing [J].
Bray, RA .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :194-200
[6]  
BROWN C, 2001, HISTOCOMPATIBILITY T
[7]  
*COM TRANSF MULT, 2005, GUIA COND HEM
[8]  
Combs M. R., 2005, TECHNICAL MANUAL
[9]   Mechanisms of transfusion-related acute lung injury (TRALI): Anti-leukocyte antibodies [J].
Curtis, BR ;
McFarland, JG .
CRITICAL CARE MEDICINE, 2006, 34 (05) :S118-S123
[10]  
Engelfriet CP, 2003, VOX SANG, V84, P73